Table 1.
List of drugs and drug classes covered, corresponding indications and SRs performed
| Drug or drug class | Indication |
|---|---|
| Proton pump inhibitors | GERD/GORD (SR-1) |
| Gastrointestinal ulcer (gastric, duodenal) (SR-1) | |
| Dyspepsia (SR-1) | |
| Anti- inflammatory and anti- rheumatic products, non-steroids (NSAIDs) | Musculoskeletal disorders (SR-2) |
| Opioids | Pain (SR-3) |
| HMG CoA reductase inhibitors (Statins) | Prevention of cardiovascular disease (SR-4) |
| Beta blocking agents | Hypertension (SR-5) |
| Heart failure (SR-6) | |
| Angiotensin Converting Enzyme inhibitors (ACE-I) | Hypertension (SR-7) |
| Low-ceiling diuretics, Thiazides and Sulfonamides | Heart failure (SR-8) |
| Oedema (SR-8) | |
| Hypertension (SR-9) | |
| Calcium Channel Blockers (CCBs) | Angina (SR-10) |
| Hypertension (SR-11) | |
| Nitrates | Angina (SR-12) |
| High ceiling diuretics | Heart failure (SR-13) |
| Oedema (SR-13) | |
| Hypertension (SR-13) | |
| Liver failure (SR-13) | |
| Renal failure (SR-13) | |
| Platelet aggregation inhibitors | Prevention and treatment of cardiovascular disease including cerebral infarction and transient ischaemic attack, coronary disease and peripheral artery occlusive disease (SR-14) |
| Vitamin K antagonists (VKA) Direct thrombin inhibitors and Direct factor Xa inhibitors (New Oral Anticoagulants (NOACs)) | Deep vein thrombosis/lung embolism (SR-15) |
| Thromboembolism in atrial fibrillation (SR-16) | |
| Digitalis glycosides | Heart failure (SR-17) |
| Atrial fibrillation (SR-17) | |
| Metformin | Type 2 diabetes (SR-18) |
| Dipeptidyl peptidase 4 (DPP-4) inhibitors (Gliptins) | Type 2 diabetes (SR-19) |
| Pioglitazone | Type 2 diabetes (SR-20) |
| Sulfonylureas | Type 2 diabetes (SR-21) |
| Glinides | Type 2 diabetes (SR-21) |
| Insulin and analogues | Type 2 diabetes (SR-22) |
GERD gastroesophageal reflux disease, GORD gastro-oesophageal reflux disease, HMG CoA 3-hydroxy-3-methylglutaryl-coenzyme A, Direct factor Xa inhibitors xabans